Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akihiro Watari

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 16, 2018
Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2Yosuke Hashimoto, Tomoyuki Hata, Minoru Tada, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2015
Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virusMayo Yamashita, Manami Iida, Minoru Tada, et al.
International Journal of Cancer|April 29, 2006
Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphomaMisuzu Shimakage, Nobumasa Inoue, Kohichi Ohshima, et al.
Biochemical and Biophysical Research Communications|June 12, 2016
Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse modelYosuke Hashimoto, Minoru Tada, Manami Iida, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 4, 2015
Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte ModelMisaki Nakajima, Shotaro Nagase, Manami Iida, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 19, 2017
Claudin-5-Binders Enhance Permeation of Solutes across the Blood-Brain Barrier in a Mammalian ModelYosuke Hashimoto, Keisuke Shirakura, Yoshiaki Okada, et al.
Scientific Reports|November 8, 2017
Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assayAkihiro Watari, Miki Kodaka, Koji Matsuhisa, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 21, 2017
Creation of a Claudin-2 Binder and Its Tight Junction-Modulating Activity in a Human Intestinal ModelMutsumi Takigawa, Manami Iida, Shotaro Nagase, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 14, 2018
Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous systemSatoshi Zeniya, Hiroya Kuwahara, Kaiichi Daizo, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 14, 2014
Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapyXiangru Li, Manami Iida, Minoru Tada, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 16, 2018
Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2Yosuke Hashimoto, Tomoyuki Hata, Minoru Tada, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2015
Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virusMayo Yamashita, Manami Iida, Minoru Tada, et al.
International Journal of Cancer|April 29, 2006
Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphomaMisuzu Shimakage, Nobumasa Inoue, Kohichi Ohshima, et al.
Biochemical and Biophysical Research Communications|June 12, 2016
Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse modelYosuke Hashimoto, Minoru Tada, Manami Iida, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 4, 2015
Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte ModelMisaki Nakajima, Shotaro Nagase, Manami Iida, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 19, 2017
Claudin-5-Binders Enhance Permeation of Solutes across the Blood-Brain Barrier in a Mammalian ModelYosuke Hashimoto, Keisuke Shirakura, Yoshiaki Okada, et al.
Scientific Reports|November 8, 2017
Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assayAkihiro Watari, Miki Kodaka, Koji Matsuhisa, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 21, 2017
Creation of a Claudin-2 Binder and Its Tight Junction-Modulating Activity in a Human Intestinal ModelMutsumi Takigawa, Manami Iida, Shotaro Nagase, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 14, 2018
Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous systemSatoshi Zeniya, Hiroya Kuwahara, Kaiichi Daizo, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 14, 2014
Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapyXiangru Li, Manami Iida, Minoru Tada, et al.
Pageof 4